论文部分内容阅读
[目的]探讨胃腺癌中EGFR、Her-2扩增及联合扩增情况及其与临床病理参数和生存间的关系。[方法]显色原位杂交(CISH)法检测85例胃腺癌组织中EGFR、Her-2扩增情况。[结果]胃腺癌中EGFR扩增率为15.3%,Her-2扩增率为10.6%,两者联合扩增率为7.1%。低分化、侵及浆膜外、有淋巴结转移胃腺癌EGFR基因扩增率明显增高(P<0.05),联合扩增者5年生存率低(16.7%vs74.7%,P=0.00014)。[结论]EGFR基因扩增使胃癌细胞低分化,EGFR和Her-2联合扩增的胃腺癌术后5年生存率降低。
[Objective] To investigate the amplification and co-amplification of EGFR and Her-2 in gastric adenocarcinoma and their relationship with clinicopathological parameters and survival. [Methods] The color in situ hybridization (CISH) method was used to detect the amplification of EGFR and Her-2 in 85 cases of gastric adenocarcinoma. [Results] The amplification rate of EGFR in gastric adenocarcinoma was 15.3%, the amplification rate of Her-2 was 10.6%, and the combined amplification rate of both was 7.1%. The rate of EGFR gene amplification in poorly differentiated and invaded epithelial and lymph node metastatic gastric adenocarcinomas was significantly higher (P<0.05), and the 5-year survival rate of combined amplifying patients was low (16.7% vs 74.7%, P=0.00014). [Conclusion] EGFR gene amplification made gastric cancer cells poorly differentiated, and the 5-year survival rate of gastric adenocarcinoma combined with EGFR and Her-2 amplification decreased.